stockrowAscendis Pharma A/S
ASND Healthcare Biotechnology
Ascendis Pharma A/S’s revenue for fiscal 2025 (year ended December 2025) was $814.8 million, up 107.1% from fiscal 2024.
- Revenue
- +119.9%
- EPS
- +612.3%
- Free cash flow
- +2,335.9%
- Total debt
- −41.8%
Quarter to June 2026, against a year earlier
Follow ASND
Alert me
Ascendis Pharma A/S (ASND) Debt to equity
Ascendis Pharma A/S's debt to equity at the end of the quarter to 30 June 2026 was 0.3×, up 5.7× from fiscal 2025 (−5.4×). Over the past ten years it has ranged from −8.1× (fiscal 2024) to 1.9× (fiscal 2022); the current reading is higher than 18% of that period. That is above the Biotechnology industry median of 0.0× and above the Healthcare sector median of 0.0×.
Debt to equity, annual
Embed this chart
Annual newest first
| Period | Debt to equity | Change |
|---|---|---|
| FY2025 | −5.4× | — |
| FY2024 | −8.1× | — |
| FY2023 | −3.7× | — |
| FY2022 | 1.9× | 1,596.31% |
| FY2021 | 0.1× | (2.65%) |
| FY2020 | 0.1× | 90.70% |
| FY2019 | 0.1× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Debt to equity | Change |
|---|---|---|
| Jun 2026 | 0.3× | (82.95%) |
| Mar 2026 | 1.8× | — |
| Dec 2025 | −5.4× | — |
| Sep 2025 | −4.7× | — |
| 42 more quarters | Free account |
Against its own ten years
Debt to equity against peers
| Company | Debt to equity |
|---|---|
| HALO Halozyme Therapeutics, Inc. compare | −58.8× |
| BBIO BridgeBio Pharma, Inc. compare | −1.2× |
| EXEL Exelixis, Inc. compare | 0.0× |
| SMMT Summit Therapeutics PLC compare | 0.0× |
| BNTX BioNTech SE Sponsored ADR compare | 0.0× |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 0.3× |
| ASND Ascendis Pharma A/S | 0.3× |
| INSM Insmed, Inc. compare | 0.8× |
| JAZZ Jazz Pharmaceuticals PLC compare | 1.3× |
| Biotechnology industry median | 0.0× |
| Healthcare sector median | 0.0× |
| Market median | 0.1× |
What Debt to equity is
Debt to Equity Ratio shows how much a company relies on borrowed money compared with the money its shareholders have in the business.
(Long Term Debt (Total) + Current Part of Debt) ÷ Shareholders Equity (Total)
More on ASND
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement